SCHEMBL4149209

SCHEMBL4149209

N[C@H](CO)c1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 5/20 0.53
CYP1A2 P05177 1/20 0.49
S1PR4 O95977 3/20 0.48
S1PR1 P21453 3/20 0.48
S1PR5 Q9H228 3/20 0.48
TAAR1 Q96RJ0 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41
BACE1 P56817 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
GAA P10253 1/20 0.40
AAK1 Q2M2I8 1/20 0.38
KDM4E B2RXH2 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.37
HRH4 Q9H3N8 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5101032 1.00 SCN10A (0.53) SCN10ACYP1A2S1PR4S1PR1S1PR5
SCHEMBL5100732 1.00 SCN10A (0.53) SCN10ACYP1A2S1PR4S1PR1S1PR5
SCHEMBL5099820 0.88 CYP1A2 (0.44) SCN10ACYP1A2S1PR4S1PR1S1PR5
SCHEMBL580331 0.85 TAAR1 (0.46) SCN10ACYP1A2S1PR4S1PR1S1PR5
SCHEMBL5109491 0.83 SCN10A (0.57) SCN10ACYP1A2TAAR1GAARAB9A
SCHEMBL5794188 0.83 SCN10A (0.45) SCN10ACYP1A2TAAR1RAB9A
SCHEMBL5109489 0.83 SCN10A (0.57) SCN10ACYP1A2TAAR1GAARAB9A
SCHEMBL5111130 0.82 TAAR1 (0.65) TAAR1AAK1
SCHEMBL5110667 0.82 SCN10A (0.56) SCN10ACYP1A2S1PR4S1PR1S1PR5
SCHEMBL5110212 0.82 TAAR1 (0.43) SCN10ACYP1A2S1PR4S1PR1S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-07-16 US disclosed
US-7429597-B2 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-09-30 US disclosed
EP-1583757-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2005-10-12 EP disclosed
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-09 US disclosed
WO-2004058743-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions F11, F12, F2 SCN10A 485/4885CYP1A2 98/4885S1PR4 4711/4885
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 SCN10A 420/4885CYP1A2 87/4885S1PR4 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.